Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Trial record 1 of 3 for:    13-E-0015
Previous Study | Return to List | Next Study

Environmental Risk Factors for Myositis in Military Personnel

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2014 by National Institutes of Health Clinical Center (CC)
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Institute of Environmental Health Sciences (NIEHS) )
ClinicalTrials.gov Identifier:
NCT01734369
First received: November 22, 2012
Last updated: October 17, 2014
Last verified: May 2014

November 22, 2012
October 17, 2014
October 2012
September 2015   (final data collection date for primary outcome measure)
Military Myositis Questionnaire [ Time Frame: Time of enrollment ] [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT01734369 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Environmental Risk Factors for Myositis in Military Personnel
Environmental Risk Factors for the Development of Myositis in Military Personnel

Background:

  • Myositis is a rare disease in which the body s immune cells attack the muscle tissue. It can cause muscle weakness, swelling, and pain. It can develop in people with no history of muscle problems. Environmental exposures may determine who develops myositis. Genes may also affect development of the disease.
  • Some people who serve in the military develop myositis. However, other military personnel do not. Researchers want to compare military personnel with and without myositis. They will look for common factors that might have led to the disease.

Objectives:

- To study environmental risk factors for myositis in military personnel.

Eligibility:

  • Military personnel who developed myositis during their period of service.
  • Healthy military personnel who do not have myositis or another autoimmune disease.

Design:

  • Participants will have a physical exam and medical history.
  • Participants will fill out forms about environmental exposures, particularly while in the military. The questions will ask about past infections, vaccines and medications, and personal habits. They will also ask about participants occupations during military service and their deployments.
  • Participants will also provide blood samples for study.
  • No treatment will be provided as part of this study.

Myositis, an autoimmune muscle disease, likely develops as a result of environmental exposures in genetically susceptible persons. Preliminary data suggest a trend for an increasing incidence in myositis in military personnel over the last decade for unknown reasons. Although a few environmental exposures have been preliminarily associated with myositis in the civilian population, these have not been confirmed. In addition, no study has assessed exposures that might result in the development of myositis in military personnel. Military personnel experience a number of intense, unique exposures, often over a relatively short interval, which include different stresses, novel vaccines, distinct occupational exposures, battlefield injuries and unique chemicals during field deployment, that differ from those exposures in non-military populations. Therefore, we propose a protocol that consists of three complementary approaches to attempt to determine the environmental factors associated with the development of myositis in active duty military personnel and an initial understanding of the possible mechanisms involved. In the first approach, we will assess risk factors in a case-control study of 300 patients who developed myositis while on active duty by comparing them to 1500 active duty military personnel (randomly selected, but matched 5:1 by gender, race, and age and military service within 10 years) who have not been diagnosed with an autoimmune disease or chronic muscle disease. For this first approach, we will analyze existing military databases for information on medications, vaccines, infections, co-existing medical conditions, military occupations, deployments, and worldwide active duty locations. In the second case-control approach, we will attempt to define environmental factors associated with the development of myositis that developed in military personnel (n=150) by comparing them to 150 similarly matched military personnel who have not been diagnosed with an autoimmune disease or chronic muscle disease. This second approach will differ from the first approach, in that subjects will be prospectively enrolled and assessed during a single clinic visit to confirm diagnoses and examine patient questionnaires on focused environmental exposures, including those not captured in the military databases. A third laboratory approach will identify, in an exploratory study, the global DNA methylation epigenetic changes, microRNA and mRNA profiles in peripheral blood and muscle tissues from 18 subjects (six PM and six DM compared to six non-myositis controls enrolled in the second approach) and assess the effects of selected environmental exposures on these parameters. These complementary approaches should enhance the understanding of environmental factors and possible mechanisms associated with the development of myositis in the military, and provide insights into environmental risk factors that may also be relevant to the development of myositis in non-military populations.

Observational
Not Provided
Not Provided
Not Provided
Not Provided
Not Provided
  • Dermatomyositis
  • Adult Polymyositis
  • Inclusion Body Myositis
  • Myositis
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
300
September 2015
September 2015   (final data collection date for primary outcome measure)
  • ELIGIBILITY CRITERIA:

For Aim 1 of the study:

The inclusion criteria for myositis subjects are:

-Diagnosis of PM, DM or IBM during military service. Subjects may be active duty or no longer active duty personnel. A matrix diagnosis of myositis will be based on ICD-9 codes, laboratory tests and medical records in an attempt to match criteria for probable or definite PM, DM or IBM

The inclusion criteria for matched control subjects are:

-The same gender, race, age within 10 years, and service in the military within 10 years as the myositis subject.

The exclusion criteria for control subjects are:

-A matrix diagnosis of autoimmune or chronic muscle disease based on ICD-9 codes and medical records (Appendix 2).

For Aims 2 and 3 of the study:

The inclusion criteria for enrollment of myositis subjects are:

  • Diagnosis of myositis during military service based on criteria for probable or definite PM or DM, or clinically or pathologically defined or possible IBM. Subjects may be active duty or no longer active duty personnel.
  • Able and willing to give informed consent, to complete the questionnaires and to donate blood samples.

The inclusion criteria for matched controls are:

  • Persons with military experience attending the same clinic or hospital as the myositis subject to which they are matched, or if not available, volunteers from the general community (such as other participating military or VA hospitals, private HCPs, or the NIH Normal volunteer program), gender- race- and age- (within 10 years) and military service period (within 10 years) matched to the myositis subject.
  • Controls should be without a recognized autoimmune or chronic muscle disease, able and willing to give informed consent, to complete the questionnaires and to donate blood samples.

The exclusion criteria for all protocol subjects are:

  • Medical illness that in the judgment of the investigators does not allow safe blood draws or other clinical evaluations needed for study participation.
  • Chronic muscle diseases other than idiopathic inflammatory myopathy (i.e. infectious, dystrophic, metabolic, toxic or drug-induced myopathies).
  • Cognitive impairment.
  • Not able or willing to give informed consent.
  • Age < 18 years.

There are no gender or ethnic restrictions to enrollment in the study.

Both
18 Years to 90 Years
Yes
Contact: Komal B Patel (301) 443-6053 komal.patel@nih.gov
United States
 
NCT01734369
130015, 13-E-0015
Not Provided
National Institutes of Health Clinical Center (CC) ( National Institute of Environmental Health Sciences (NIEHS) )
National Institute of Environmental Health Sciences (NIEHS)
Not Provided
Principal Investigator: Frederick W Miller, M.D. National Institute of Environmental Health Sciences (NIEHS)
National Institutes of Health Clinical Center (CC)
May 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP